Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.34 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.33 |
| ▸ | PNMT | P11086 | 1/20 | 0.33 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2112783 | 1.00 | HTR2A (0.42) | HTR2AHTR2CHTR2BIDO1TDP1 | |
| SCHEMBL2610198 | 0.90 | HTR2A (0.41) | HTR2AHTR2CHTR2BIDO1TDP1 | |
| SCHEMBL1109727 | 0.75 | IDO1 (0.47) | HTR2AIDO1 | |
| SCHEMBL28971366 | 0.75 | IDO1 (0.47) | HTR2AIDO1 | |
| SCHEMBL7108519 | 0.75 | IDO1 (0.47) | HTR2AIDO1 | |
| SCHEMBL5852603 | 0.75 | IDO1 (0.47) | HTR2AIDO1 | |
| SCHEMBL10283627 | 0.75 | ALDH1A1 (0.35) | TDP1 | |
| SCHEMBL9735314 | 0.75 | DRD2 (0.49) | IDO1PNMTKDM1A | |
| SCHEMBL4119570 | 0.75 | CYP19A1 (0.49) | HTR2AHTR2CHTR2BKDM1A | |
| SCHEMBL20241214 | 0.73 | HTR2A (0.47) | HTR2AHTR2CHTR2BIDO1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227468-B2 | Cathepsin S inhibitor compounds | ELI LILLY AND COMPANY (US) | 2012-07-24 | — | — | US | disclosed |
| US-8227468-B2 | Cathepsin S inhibitor compounds | ELI LILLY AND COMPANY (US) | 2012-07-24 | — | — | US | disclosed |
| US-20120095020-A1 | Cathepsin S Inhibitor Compounds | ELI LILLY AND COMPANY (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120095020-A1 | Cathepsin S Inhibitor Compounds | ELI LILLY AND COMPANY (US) | 2012-04-19 | — | — | US | disclosed |
| US-7612061-B2 | Piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2009-11-03 | — | — | US | disclosed |
| US-20090076030-A1 | Piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2009-03-19 | — | — | US | disclosed |
| US-20090075982-A1 | Piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2009-03-19 | — | — | US | disclosed |
| US-7465733-B2 | Piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2008-12-16 | — | — | US | disclosed |
| EP-1710240-B1 | Piperazine derivatives and their use as serotonin reuptake inhibitors or as neurokinin antagonists | SERVIER LAB (FR) | 2007-12-05 | — | — | EP | disclosed |
| US-20060229318-A1 | Piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2006-10-12 | — | — | US | disclosed |
| EP-1710240-A1 | Piperazine derivatives and their use as serotonin reuptake inhibitors or as neurokinin antagonists | Les Laboratoires Servier (FR) | 2006-10-11 | — | — | EP | disclosed |
| US-5132307-A | TETRALIN COMPOUNDS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1992-07-21 | — | — | US | disclosed |
| EP-0368160-A1 | Tetralin derivatives | MERCK PATENT GmbH (DE) | 1990-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095020-A1 | Cathepsin S Inhibitor Compounds | CTSS, CTSZ, CTSV | HTR2A 4606/4885HTR2C 4757/4885HTR2B 4071/4885 |
| US-20090075982-A1 | Piperazine compounds | HTR7, HTR5A, NPY5R | HTR2A 22/4885HTR2C 18/4885HTR2B 47/4885 |
| US-20090076030-A1 | Piperazine compounds | HTR7, HTR5A, NPY5R | HTR2A 22/4885HTR2C 18/4885HTR2B 47/4885 |
| US-20060229318-A1 | Piperazine compounds | HTR7, HTR5A, NPY5R | HTR2A 22/4885HTR2C 18/4885HTR2B 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.